Targeting CT47A10 for Breast Cancer (G728036)

Target Name: CT47A10

NCBI ID: G728036

CT47A10

Targeting CT47A10 for Breast Cancer

CT47A10 is a protein that is expressed in a variety of tissues throughout the body, including the breast, lung, and gastrointestinal tract. It is also a potential drug target for cancer, specifically cancer of the breast.

The protein is derived from the appendix, which is a small organ located in the intestine. It is produced by the immune system and is involved in the immune response. CT47A10 is a type of cytokine, which is a protein that is produced by the immune system to help stimulate an immune response.

In cancer, CT47A10 has been shown to be overexpressed in a variety of breast cancers. This means that the level of CT47A10 in the breast tissue is higher than in other tissues. High levels of CT47A10 have been associated with the development and progression of breast cancer, including the most aggressive types.

One potential way to target CT47A10 in cancer is to use drugs that specifically inhibit its activity. For example, researchers have developed compounds that can bind to CT47A10 and prevent it from interacting with its receptors. These drugs have been shown to be effective in preclinical studies in treating breast cancer.

Another approach to targeting CT47A10 is to use antibodies that are designed to selectively bind to the protein. These antibodies have been shown to be effective in preclinical studies in treating breast cancer.

Targeting CT47A10 may also be a useful way to identify new biomarkers for breast cancer. By using antibodies or drugs that specifically bind to CT47A10, researchers can identify proteins that are involved in the development and progression of breast cancer. This may help to improve our understanding of the underlying causes of breast cancer and could lead to the development of new, more effective treatments.

Overall, CT47A10 is a protein that is expressed in a variety of tissues throughout the body and has been shown to be involved in the immune response. It is also a potential drug target for cancer, specifically breast cancer. Further research is needed to fully understand its role and potential as a therapeutic target.

Protein Name: Cancer/testis Antigen Family 47 Member A10

The "CT47A10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT47A10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets